<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>JARDIANCE- empagliflozinÂ tablet, film coatedÂ </strong><br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information
needed to use JARDIANCE safely and effectively.  See full prescribing
information for JARDIANCE.<br><br>JARDIANCE<span class="Sup">Â®</span> (empagliflozin) tablets, for oral use<br>Initial
U.S. Approval: 2014<br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">JARDIANCE is a sodium-glucose co-transporter
2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to
improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (<a href="#Section_1">1</a>) </p>
<br><p class="ListCaption">Limitation of Use:</p>
<ul class="Disc"><li>Not for the treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or diabetic
<span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> (<a href="#Section_1.1">1.1</a>)</li></ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>The recommended dose of JARDIANCE is 10 mg once daily, taken
in the morning, with or without food (<a href="#Section_2.1">2.1</a>)</li>
<li>Dose may be increased to 25 mg once daily (<a href="#Section_2.1">2.1</a>)</li>
<li>Assess renal function before initiating JARDIANCE.  Do not
initiate JARDIANCE if eGFR is below 45 mL/min/1.73 m<span class="Sup">2</span> (<a href="#Section_2.2">2.2</a>)</li>
<li>Discontinue JARDIANCE if eGFR <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> persistently below 45
mL/min/1.73 m<span class="Sup">2</span> (<a href="#Section_2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets:  10 mg, 25 mg (<a href="#Section_3">3</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to JARDIANCE
(<a href="#Section_4">4</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or dialysis
(<a href="#Section_4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span> Before initiating JARDIANCE
assess and correct volume status in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>,
the elderly, in patients with low systolic blood pressure, and in
patients on diuretics. Monitor for signs and symptoms during therapy.
(<a href="#Section_5.1">5.1</a>)</li>
<li>
<span class="Italics">Impairment in renal function:</span> Monitor renal
function during therapy.  More frequent monitoring is recommended
in patients with eGFR below 60 mL/min/1.73 m<span class="Sup">2</span> (<a href="#Section_5.2">5.2</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span> Consider lowering the dose
of insulin secretagogue or insulin to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>
when initiating JARDIANCE (<a href="#Section_5.3">5.3</a>)</li>
<li>
<span class="Italics">Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</span> Monitor and
treat as appropriate (<a href="#Section_5.4">5.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span>:</span> Monitor and treat
as appropriate (<a href="#Section_5.5">5.5</a>)</li>
<li>
<span class="Italics">Increased LDL-C:</span> Monitor and treat as appropriate
(<a href="#Section_5.6">5.6</a>)</li>
<li>
<span class="Italics">Macrovascular outcomes:</span> There have been
no clinical studies establishing conclusive evidence of macrovascular
risk reduction with JARDIANCE (<a href="#Section_5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>The most common adverse reactions associated with JARDIANCE
 (5% or greater incidence) were <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> and female
genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#Section_6.1">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257
or 1-800-459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<br>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Pregnancy:</span> No adequate and well-controlled
studies in pregnant women.  Use during pregnancy only if the potential
benefit justifies the potential risk to the fetus. (<a href="#Section_8.1">8.1</a>)</li>
<li>
<span class="Italics">Nursing mothers:</span> Discontinue JARDIANCE
or discontinue nursing (<a href="#Section_8.3">8.3</a>)</li>
<li>
<span class="Italics">Geriatric patients:</span> Higher incidence of
adverse reactions related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> and reduced renal function
(<a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>, <a href="#Section_8.5">8.5</a>)</li>
<li>
<span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>:</span> Higher
incidence of adverse reactions related to reduced renal function (<a href="#Section_2.2">2.2</a>, <a href="#Section_5.2">5.2</a>, <a href="#Section_8.6">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1â€ƒâ€ƒINDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3â€ƒâ€ƒDOSAGE
FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4â€ƒâ€ƒCONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Impairment in Renal Function</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Increased Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6â€ƒâ€ƒADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials
Experience</a></h2>
<h1><a href="#section-7" class="toc">7â€ƒâ€ƒDRUG
INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Diuretics</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Insulin or Insulin Secretagogues</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Positive Urine Glucose Test</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Interference with 1,5-anhydroglucitol (1,5-AG) Assay</a></h2>
<h1><a href="#section-8" class="toc">8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10â€ƒâ€ƒOVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11â€ƒâ€ƒDESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12â€ƒâ€ƒCLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14â€ƒâ€ƒCLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Monotherapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination Therapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-14" class="toc">16â€ƒâ€ƒHOW
SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1â€ƒâ€ƒINDICATIONS AND USAGE</h1>
<p class="First"><a name="p314281403549223"></a>JARDIANCE is indicated as an adjunct to diet
and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
mellitus <span class="Italics">[see Clinical Studies (<a href="#Section_14">14</a>)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Limitation of Use</h2>
<p class="First"><a name="p27612221360080443"></a>JARDIANCE is not recommended for
patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosage</h2>
<p class="First"><a name="p51398221360080576"></a>The recommended dose of JARDIANCE
is 10 mg once daily in the morning, taken with or without food.  In
patients tolerating JARDIANCE, the dose may be increased to 25 mg <span class="Italics">[see Clinical Studies (<a href="#Section_14">14</a>)]</span>.</p>
<p><a name="p514010221360080592"></a>In patients with
<span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, correcting this condition prior to initiation of
JARDIANCE is recommended <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>), Use in Specific Populations (<a href="#Section_8.5">8.5</a>), and Patient Counseling Information
(<a href="#Section_17">17</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p5583281407182223"></a>Assessment of renal function is recommended
prior to initiation of JARDIANCE and periodically thereafter.</p>
<p><a name="p5574281407182228"></a>JARDIANCE should not be initiated
in patients with an eGFR less than 45 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p><a name="p2536511281407182230"></a>No dose adjustment
is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73
m<span class="Sup">2</span>.</p>
<p><a name="p195054281403549353"></a>JARDIANCE should be discontinued if eGFR
is persistently less than 45 mL/min/1.73 m<span class="Sup">2</span><span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>), and Use in Specific
Populations (<a href="#Section_8.6">8.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3â€ƒâ€ƒDOSAGE
FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>JARDIANCE (empagliflozin) 10 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow,
round, biconvex and bevel-edged, film-coated tablets debossed with
â€œS 10â€? on one side and the Boehringer Ingelheim company symbol on
the other side.</li>
<li>JARDIANCE (empagliflozin) 25 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow,
oval, biconvex, film-coated tablets debossed with â€œS 25â€? on one side
and the Boehringer Ingelheim company symbol on the other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4â€ƒâ€ƒCONTRAINDICATIONS</h1>
<ul class="Disc">
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to JARDIANCE.</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or dialysis <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>)]</span>.</li>
</ul>
<p class="First"><a name="P8"></a></p>
<p><a name="p253704281403549726"></a></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First"><a name="p202354281403549843"></a>JARDIANCE causes intravascular volume contraction.  Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>
may occur after initiating JARDIANCE <span class="Italics">[see Adverse Reactions
(<a href="#Section_6.1">6.1</a>)]</span> particularly in patients
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the elderly, in patients with low systolic
blood pressure, and in patients on diuretics.  Before initiating JARDIANCE,
assess for volume contraction and correct volume status if indicated.
 Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after initiating therapy
and increase monitoring in clinical situations where volume contraction
is expected <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.5">8.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Impairment in Renal Function</h2>
<p class="First"><a name="p43871221360080891"></a>JARDIANCE increases serum creatinine and decreases
eGFR <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.  The risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> with JARDIANCE
is increased in elderly patients and patients with moderate renal
impairment.  More frequent monitoring of renal function is recommended
in these patients <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.5">8.5</a>, <a href="#Section_8.6">8.6</a>)]</span>.  Renal function should be evaluated prior to initiating
JARDIANCE and periodically thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</h2>
<p class="First"><a name="p566913221360080922"></a>Insulin and insulin secretagogues
are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  The risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is increased
when JARDIANCE is used in combination with insulin secretagogues (e.g.,
sulfonylurea) or insulin <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.  Therefore, a lower dose
of the insulin secretagogue or insulin may be required to reduce the
risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with JARDIANCE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First"><a name="p253916281403550018"></a>JARDIANCE increases the risk for genital
mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.  Patients with a history
of chronic or recurrent genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more likely
to develop mycotic <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infections</span>.  Monitor and treat as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First"><a name="p256075281403550073"></a>JARDIANCE increases the risk for urinary
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.  Monitor and treat as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Increased Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)</h2>
<p class="First"><a name="p202426281403550155"></a>Increases in LDL-C can occur
with JARDIANCE <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.  Monitor and treat as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Macrovascular Outcomes</h2>
<p class="First"><a name="p258801281403550158"></a>There have been no clinical studies establishing
conclusive evidence of macrovascular risk reduction with JARDIANCE
or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6â€ƒâ€ƒADVERSE REACTIONS</h1>
<p class="First"><a name="p256090281403550260"></a>The following important adverse reactions
are described below and elsewhere in the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)]</span>
</li>
<li>Impairment in Renal Function<span class="Italics"> [see Warnings and Precautions
(<a href="#Section_5.2">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin
Secretagogues<span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.3">5.3</a>)]</span>
</li>
<li>Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span><span class="Italics"> [see Warnings and Precautions
(<a href="#Section_5.4">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.5">5.5</a>)]</span>
</li>
<li>Increased Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)<span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.6">5.6</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials
Experience</h2>
<p class="First"><a name="p461011221360080982"></a>Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot
be directly compared to rates in the clinical trials of another drug
and may not reflect the rates observed in practice.</p>
<p><a name="p307414281407182726"></a><span class="Underline">Pool of Placebo-Controlled Trials
evaluating JARDIANCE 10 and 25 mg</span><br>The data
in Table 1 are derived from a pool of four 24-week placebo-controlled
trials and 18-week data from a placebo-controlled trial with insulin.
 JARDIANCE was used as monotherapy in one trial and as add-on therapy
in four trials <span class="Italics">[see Clinical Studies (<a href="#Section_14">14</a>)]</span>.</p>
<p><a name="p307319281407182721"></a>These data reflect exposure of 1976 patients to JARDIANCE with a
mean exposure duration of approximately 23 weeks.  Patients received
placebo (N=995), JARDIANCE 10 mg (N=999), or JARDIANCE 25 mg (N=977)
once daily.  The mean age of the population was 56 years and 3% were
older than 75 years of age.  More than half (55%) of the population
was male; 46% were White, 50% were Asian, and 3% were Black or African
American.  At baseline, 57% of the population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> more than
5 years and had a mean hemoglobin A1c (HbA1c) of 8%.  Established
microvascular complications of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> at baseline included diabetic
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (7%), <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (8%), or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (16%).  Baseline
renal function was normal or mildly impaired in 91% of patients and
moderately impaired in 9% of patients (mean eGFR 86.8 mL/min/1.73
m<span class="Sup">2</span>).</p>
<p><a name="p307394281407182726"></a>Table 1 shows common adverse reactions (excluding
<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) associated with the use of JARDIANCE.  The adverse reactions
were not present at baseline, occurred more commonly on JARDIANCE
than on placebo and occurred in greater than or equal to 2% of patients
treated with JARDIANCE 10 mg or JARDIANCE 25 mg.</p>
<a name="t30763528"></a><table border="0" frame="void" rules="none" width="100%">
<caption><span>Table 1â€ƒAdverse Reactions Reported in â‰¥2% of Patients Treated
with JARDIANCE and Greater than Placebo in Pooled Placebo-Controlled
Clinical Studies of JARDIANCE Monotherapy  or Combination Therapy</span></caption>
<colgroup>
<col width="34%">
<col width="22%">
<col width="22%">
<col width="22%">
</colgroup>
<tfoot>
<tr class="First"><td colspan="4">
<span class="Sup">a</span>Predefined adverse event
grouping, including, but not limited to, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>,
<span class="product-label-link" type="condition" conceptid="4128402" conceptname="Asymptomatic bacteriuria">asymptomatic bacteriuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span></td></tr>
<tr><td colspan="4">
<span class="Sup">b</span>Female genital mycotic
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include the following adverse reactions: vulvovaginal mycotic
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, <span class="product-label-link" type="condition" conceptid="4269221" conceptname="Vulvitis">vulvitis</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span>,
<span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>, <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">genital candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span> fungal,
genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span>, urogenital
<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">infection fungal</span>, <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">vaginitis bacterial</span>.  Percentages calculated with
the number of female subjects in each group as denominator: placebo
(N=481), JARDIANCE 10 mg (N=443), JARDIANCE 25 mg (N=420).</td></tr>
<tr><td colspan="4">
<span class="Sup">c</span>Predefined adverse event
grouping, including, but not limited to, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, and
<span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span></td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">d</span>Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
include the following adverse reactions: <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>,
<span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infections</span> fungal, genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>
<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candida</span>, <span class="product-label-link" type="condition" conceptid="4100659" conceptname="Abscess of scrotum">scrotal abscess</span>, <span class="product-label-link" type="condition" conceptid="4205814" conceptname="Infection of penis">penile infection</span>.  Percentages calculated
with the number of male subjects in each group as denominator: placebo
(N=514), JARDIANCE 10 mg (N=556), JARDIANCE 25 mg (N=557).</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Number (%) of Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>N=995</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg<br>N=999</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg<br>N=977</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span><span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Increased urination<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Sup">d</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.6%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.1%</td>
</tr>
</tbody>
</table>
<p><a name="p307374281407182725"></a><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span> (including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>)
was reported in 0%, 1.7%, and 1.5% for placebo, JARDIANCE 10 mg, and
JARDIANCE 25 mg, respectively.</p>
<p><a name="p307336281407182723"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span></span><br>JARDIANCE causes an osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, which may lead to intravascular
volume contraction and adverse reactions related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>.
 In the pool of five placebo-controlled clinical trials, adverse reactions
related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> (e.g., blood pressure (ambulatory) decreased,
<span class="product-label-link" type="condition" conceptid="4217168" conceptname="Decreased systolic arterial pressure">blood pressure systolic decreased</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>,
<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>) were reported by 0.3%, 0.5%,
and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE
25 mg respectively.  JARDIANCE may increase the risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>
in patients at risk for volume contraction <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.1">5.1</a>) and Use in Specific
Populations (<a href="#Section_8.5">8.5</a>, <a href="#Section_8.6">8.6</a>)].</span></p>
<p><a name="p2485913281407183205"></a><span class="Italics">Increased Urination</span><br>In the pool of five placebo-controlled clinical trials, adverse
reactions of increased urination (e.g., <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, and
<span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>) occurred more frequently on JARDIANCE than on placebo (see
Table 1).  Specifically, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span> was reported by 0.4%, 0.3%, and
0.8% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE
25 mg, respectively.</p>
<p><a name="p2484513281407183204"></a><span class="Italics">Impairment in Renal Function</span><br>Use of JARDIANCE
was associated with increases in serum creatinine and decreases in
eGFR (see Table 2).  Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline
had larger mean changes <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>) and Use in Specific Populations (<a href="#Section_8.5">8.5</a>, <a href="#Section_8.6">8.6</a>)]</span>.</p>
<a name="t246251228"></a><table border="0" frame="void" rules="none" width="100%">
<caption><span>Table 2â€ƒChanges from Baseline in Serum Creatinine and eGFR
in the Pool of Four 24-week     Placebo-Controlled Studies and Renal
Impairment Study</span></caption>
<colgroup>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Subset of patients from
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> study with eGFR 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Pool of 24-Week Placebo-Controlled Studies</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Baseline Mean</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">825</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">830</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">822</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.84</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.85</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.85</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">87.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">87.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">87.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Week 12 Change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">771</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">797</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">783</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.00 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.02</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.01</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-0.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-1.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-1.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Week 24 Change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">708</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">769</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">754</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.00</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.01</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.01</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-0.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-0.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-1.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><span class="Sup">a</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Baseline</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">187</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">187</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.49</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.46</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">44.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">45.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Week 12 Change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">176</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">179</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.01</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.12</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-3.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Week 24 Change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">170</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">171</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.01</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-3.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Week 52 Change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">164</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">162</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Creatinine (mg/dL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.02</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.11</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">eGFR (mL/min/1.73
m<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-0.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-2.8</td>
</tr>
</tbody>
</table>
<p><a name="p2485314281407183203"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span><br>The incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> by study is shown in Table
3.  The incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> increased when JARDIANCE was administered
with insulin or sulfonylurea <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.3">5.3</a>)]</span>.</p>
<a name="t34091128"></a><table border="0" frame="void" rules="none" width="100%">
<caption><span>Table 3â€ƒIncidence of Overall<span class="Sup">a</span> and
Severe<span class="Sup">b</span> Hypoglycemic Events in Placebo-Controlled
Clinical Studies</span></caption>
<colgroup>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="23%">
</colgroup>
<tfoot>
<tr class="First"><td colspan="4">
<span class="Sup">a</span>Overall hypoglycemic events:
plasma or capillary glucose of less than or equal to 70 mg/dL</td></tr>
<tr><td colspan="4">
<span class="Sup">b</span>Severe hypoglycemic events:
requiring assistance regardless of blood glucose</td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">c</span>Insulin dose could not
be adjusted during the initial 18 week treatment period</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Monotherapy<br>(24 weeks)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>(n=229)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg<br>(n=224)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg<br>(n=223)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.4%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">In Combination with<br>Metformin<br>(24 weeks)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo
+ Metformin <br>(n=206)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg + Metformin<br>(n=217)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg + Metformin<br>(n=214)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.4%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">In Combination with<br>Metformin + Sulfonylurea<br>(24 weeks)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>(n=225)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg + Metformin + Sulfonylurea<br>(n=224)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg + Metformin + Sulfonylurea<br>(n=217)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16.1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11.5%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">In Combination with<br>Pioglitazone +/- Metformin<br>(24 weeks)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>(n=165)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg + Pioglitazone +/- Metformin<br>(n=165)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg + Pioglitazone +/- Metformin<br>(n=168)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.4%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">In Combination with Basal
Insulin<br>(18 weeks<span class="Sup">c</span>)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>(n=170)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
10 mg<br>(n=169)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg<br>(n=155)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28.4%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" valign="middle">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">In Combination with MDI
Insulin +/- Metformin<br>(18 weeks<span class="Sup">c</span>)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>(n=188)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">JARDIANCE 10 mg<br>(n=186)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">JARDIANCE 25 mg<br>(n=189)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Overall (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">39.8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">41.3%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Severe (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5%</td>
</tr>
</tbody>
</table>
<p><a name="p25730281407183201"></a><span class="Italics">Genital Mycotic
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br>In the pool of five placebo-controlled
clinical trials, the incidence of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g.,
vaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span> fungal,
<span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span>, and <span class="product-label-link" type="condition" conceptid="4269221" conceptname="Vulvitis">vulvitis</span>) was increased in patients
treated with JARDIANCE compared to placebo, occurring in 0.9%, 4.1%,
and 3.7% of patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE
25 mg, respectively.  Discontinuation from study due to <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>
occurred in 0% of placebo-treated patients and 0.2% of patients treated
with either JARDIANCE 10 or 25 mg.</p>
<p><a name="p257611281407183198"></a>Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred more
frequently in female than male patients (see Table 1).</p>
<p><a name="p2486610281407183193"></a><span class="product-label-link" type="condition" conceptid="4109633" conceptname="Congenital phimosis">Phimosis</span> occurred more frequently
in male patients treated with JARDIANCE 10 mg (less than 0.1%) and
JARDIANCE 25 mg (0.1%) than placebo (0%).</p>
<p><a name="p2483412281407183193"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span><br>In the pool of five placebo-controlled clinical trials,
the incidence of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>,
<span class="product-label-link" type="condition" conceptid="4128402" conceptname="Asymptomatic bacteriuria">asymptomatic bacteriuria</span>, and <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) was increased in patients
treated with JARDIANCE compared to placebo (see Table 1).  Patients
with a history of chronic or recurrent <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> were
more likely to experience a <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.  The rate of
treatment discontinuation due to <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> was 0.1%,
0.2%, and 0.1% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg,
respectively.</p>
<p><a name="p2485412281407183191"></a>Urinary
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred more frequently in female patients.  The
incidence of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> in female patients randomized
to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 16.6%, 18.4%,
and 17.0%, respectively.  The incidence of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>
in male patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE
25 mg was 3.2%, 3.6%, and 4.1%, respectively <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.5">5.5</a>) and Use in
Specific Populations (<a href="#Section_8.5">8.5</a>)]</span>.</p>
<p><a name="p2486911281407183189"></a><span class="Italics">Laboratory
Tests</span><br><span class="Underline">Increase in Low-Density Lipoprotein
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)</span><br>Dose-related increases
in low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C) were observed in patients
treated with JARDIANCE.  LDL-C increased by 2.3%, 4.6%, and 6.5% in
patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg,
respectively <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.6">5.6</a>)]</span>.  The range of mean baseline
LDL-C levels was 90.3 to 90.6 mg/dL across treatment groups.</p>
<p><a name="p248330281407183188"></a><span class="Underline">Increase in Hematocrit</span><br>In a pool of four placebo-controlled studies, median
<span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">hematocrit decreased</span> by 1.3% in placebo and increased by 2.8% in JARDIANCE
10 mg and 2.8% in JARDIANCE 25 mg treated patients.  At the end of
treatment, 0.6%, 2.7%, and 3.5% of patients with hematocrits initially
within the reference range had values above the upper limit of the
reference range with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg,
respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7â€ƒâ€ƒDRUG
INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Diuretics</h2>
<p class="First"><a name="p25919281407185324"></a>Coadministration of empagliflozin with diuretics resulted in increased
urine volume and frequency of voids, which might enhance the potential
for <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Insulin or Insulin Secretagogues</h2>
<p class="First"><a name="p25833281407185339"></a>Coadministration of empagliflozin with insulin
or insulin secretagogues increases the risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.3">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Positive Urine Glucose Test</h2>
<p class="First"><a name="p361215281407185347"></a>Monitoring glycemic control with urine glucose
tests is not recommended in patients taking SGLT2 inhibitors as SGLT2
inhibitors increase urinary glucose excretion and will lead to positive
urine glucose tests.  Use alternative methods to monitor glycemic
control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Interference with 1,5-anhydroglucitol (1,5-AG) Assay</h2>
<p class="First"><a name="p361313281407185355"></a>Monitoring glycemic control with
1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable
in assessing glycemic control in patients taking SGLT2 inhibitors.
 Use alternative methods to monitor glycemic control.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="P15"></a><span class="Italics">Pregnancy Category C</span><br>There are no adequate
and well-controlled studies of JARDIANCE in pregnant women.  JARDIANCE
should be used during pregnancy only if the potential benefit justifies
the potential risk to the fetus.</p>
<p><a name="p92214221360082898"></a>Based on results from animal studies, empagliflozin
may affect renal development and maturation. In studies conducted
in rats, empagliflozin crosses the placenta and reaches fetal tissues.
 During pregnancy, consider appropriate alternative therapies, especially
during the second and third trimesters.</p>
<p><a name="p92284221360082923"></a>Empagliflozin was not teratogenic in embryo-fetal
development studies in rats and rabbits up to 300 mg/kg/day, which
approximates 48-times and 128-times, respectively, the maximum clinical
dose of 25 mg.  At higher doses, causing maternal toxicity, malformations
of limb bones increased in fetuses at 700 mg/kg/day or 154 times the
25 mg maximum clinical dose in rats.  In the rabbit, higher doses
of empagliflozin resulted in maternal and fetal toxicity at 700 mg/kg/day,
or 139 times the 25 mg maximum clinical dose.</p>
<p><a name="p64354281403554866"></a>In pre- and postnatal development studies
in pregnant rats, empagliflozin was administered from gestation day
6 through to lactation day 20 (weaning) at up to 100 mg/kg/day (approximately
16 times the 25 mg maximum clinical dose) without maternal toxicity.
 Reduced body weight was observed in the offspring at greater than
or equal to 30 mg/kg/day (approximately 4 times the 25 mg maximum
clinical dose).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="P17"></a>It is not known if JARDIANCE is excreted in human milk. 
Empagliflozin is secreted in the milk of lactating rats reaching levels
up to 5 times higher than that in maternal plasma. Since human kidney
maturation occurs <span class="Italics">in utero</span> and during the first 2
years of life when lactational exposure may occur, there may be risk
to the developing human kidney.  Because many drugs are excreted in
human milk and because of the potential for serious adverse reactions
in nursing infants from JARDIANCE, a decision should be made whether
to discontinue nursing or to discontinue JARDIANCE, taking into account
the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="P18"></a>The safety and effectiveness of JARDIANCE in pediatric patients
under 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="P19"></a>No JARDIANCE dosage change is recommended based on age <span class="Italics">[see Dosage and Administration (<a href="#Section_2">2</a>)]</span>.  A total of 2721 (32%) patients treated with empagliflozin were
65 years of age and older, and 491 (6%) were 75 years of age and older.
 JARDIANCE is expected to have diminished efficacy in elderly patients
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>)]</span>.  The risk of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>-related
adverse reactions increased in patients who were 75 years of age and
older to 2.1%, 2.3%, and 4.4% for placebo, JARDIANCE 10 mg, and JARDIANCE
25 mg.  The risk of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> increased in patients
who were 75 years of age and older to 10.5%, 15.7%, and 15.1% in patients
randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>) and Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p386414221360083070"></a>The efficacy and safety of JARDIANCE
were evaluated in a study of patients with mild and moderate renal
impairment <span class="Italics">[see Clinical Studies (<a href="#Section_14.3">14.3</a>)]</span>.  In this study, 195 patients exposed to JARDIANCE
had an eGFR between 60 and 90 mL/min/1.73 m<span class="Sup">2</span>, 91 patients exposed to JARDIANCE had an eGFR between 45 and 60
mL/min/1.73 m<span class="Sup">2</span> and 97 patients exposed
to JARDIANCE had an eGFR between 30 and 45 mL/min/1.73 m<span class="Sup">2</span>.  The glucose lowering benefit of JARDIANCE 25 mg
decreased in patients with worsening renal function.  The risks of
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>)]</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> adverse
reactions and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>-related adverse reactions increased
with worsening renal function.</p>
<p><a name="p256029281407185665"></a>The efficacy and safety of JARDIANCE have
not been established in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, with
ESRD, or receiving dialysis.  JARDIANCE is not expected to be effective
in these patient populations<span class="Italics"> [see Dosage and Administration
(<a href="#Section_2.2">2.2</a>), Contraindications (<a href="#Section_4">4</a>) and Warnings and Precautions (<a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p38691221360083139"></a>JARDIANCE may be used in patients
with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10â€ƒâ€ƒOVERDOSAGE</h1>
<p class="First"><a name="P24"></a>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with JARDIANCE, contact the Poison Control
Center.  Employ the usual supportive measures (e.g., remove unabsorbed
material from the gastrointestinal tract, employ clinical monitoring,
and institute supportive treatment) as dictated by the patientâ€™s clinical
status.  Removal of empagliflozin by hemodialysis has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11â€ƒâ€ƒDESCRIPTION</h1>
<p class="First"><a name="P25"></a>JARDIANCE tablets contain empagliflozin, an orally-active
inhibitor of the sodium-glucose co-transporter 2 (SGLT2).</p>
<p><a name="p38772221360083323"></a>The chemical name of empagliflozin
is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-,
(1S).</p>
<p><a name="p38743221360083333"></a>Its molecular
formula is C<span class="Sub">23</span>H<span class="Sub">27</span>ClO<span class="Sub">7</span> and the molecular weight is 450.91. The structural
formula is:</p>
<div class="Figure"><img alt="empagliflozin-struct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=empagliflozin-struct.jpg"></div>
<p><a name="p285311221360087720"></a>Empagliflozin is a white to yellowish, non-hygroscopic
powder.  It is very slightly soluble in water, sparingly soluble in
methanol, slightly soluble in ethanol and acetonitrile; soluble in
50% acetonitrile/water; and practically insoluble in toluene.</p>
<p><a name="p28270221360087722"></a>Each film-coated tablet of JARDIANCE
contains 10 mg or 25 mg of empagliflozin (free base) and the following
inactive ingredients: lactose monohydrate, microcrystalline cellulose,
hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon
dioxide and magnesium stearate.  In addition, the film coating contains
the following inactive ingredients: hypromellose, titanium dioxide,
talc, polyethylene glycol, and yellow ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12â€ƒâ€ƒCLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="P27"></a>Sodium-glucose co-transporter 2 (SGLT2) is the predominant
transporter responsible for reabsorption of glucose from the glomerular
filtrate back into the circulation.  Empagliflozin is an inhibitor
of SGLT2.  By inhibiting SGLT2, empagliflozin reduces renal reabsorption
of filtered glucose and lowers the renal threshold for glucose, and
thereby increases urinary glucose excretion.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s2054424"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><a name="p2050224"></a><span class="Italics">Urinary Glucose Excretion</span><br>In patients
with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, urinary glucose excretion increased immediately
following a dose of JARDIANCE and was maintained at the end of a 4-week
treatment period averaging at approximately 64 grams per day with
10 mg empagliflozin and 78 grams per day with 25 mg JARDIANCE once
daily <span class="Italics">[see Clinical Studies (<a href="#Section_14">14</a>)].</span></p>
<p><a name="p284614221360087815"></a><span class="Italics">Urinary Volume</span><br>In a 5-day study, mean 24-hour
urine volume increase from baseline was 341 mL on Day 1 and 135 mL
on Day 5 of empagliflozin 25 mg once daily treatment.</p>
<p><a name="p286010221360087817"></a><span class="Italics">Cardiac Electrophysiology</span><br>In a randomized, placebo-controlled, active-comparator,
crossover study, 30 healthy subjects were administered a single oral
dose of JARDIANCE 25 mg, JARDIANCE 200 mg (8 times the maximum dose),
moxifloxacin, and placebo.  No increase in QTc was observed with either
25 mg or 200 mg empagliflozin.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="P28"></a><span class="Italics">Absorption</span><br>The pharmacokinetics
of empagliflozin has been characterized in healthy volunteers and
patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and no clinically relevant differences
were noted between the two populations.  After oral administration,
peak plasma concentrations of empagliflozin were reached at 1.5 hours
post-dose.  Thereafter, plasma concentrations declined in a biphasic
manner with a rapid distribution phase and a relatively slow terminal
phase.  The steady state mean plasma AUC and C<span class="Sub">max</span> were 1870 nmolÂ·h/L and 259 nmol/L, respectively, with 10 mg empagliflozin
once daily treatment, and 4740 nmolÂ·h/L and 687 nmol/L, respectively,
with 25 mg empagliflozin once daily treatment.  Systemic exposure
of empagliflozin increased in a dose-proportional manner in the therapeutic
dose range.  The single-dose and steady-state pharmacokinetic parameters
of empagliflozin were similar, suggesting linear pharmacokinetics
with respect to time.</p>
<p><a name="p974415221360088070"></a>Administration of 25 mg empagliflozin after intake of a high-fat
and high-calorie meal resulted in slightly lower exposure; AUC decreased
by approximately 16% and C<span class="Sub">max</span> decreased by
approximately 37%, compared to fasted condition.  The observed effect
of food on empagliflozin pharmacokinetics was not considered clinically
relevant and empagliflozin may be administered with or without food.</p>
<p><a name="p974613221360088072"></a><span class="Italics">Distribution</span><br>The apparent steady-state volume of distribution was
estimated to be 73.8 L based on a population pharmacokinetic analysis.
 Following administration of an oral [<span class="Sup">14</span>C]-empagliflozin solution to healthy subjects, the red blood cell
partitioning was approximately 36.8% and plasma protein binding was
86.2%.</p>
<p><a name="p974813221360088073"></a><span class="Italics">Metabolism</span><br>No major metabolites of empagliflozin were detected in
human plasma and the most abundant metabolites were three glucuronide
conjugates (2-O-, 3-O-, and 6-O-glucuronide).  Systemic exposure of
each metabolite was less than 10% of total drug-related material.
 <span class="Italics">In vitro</span> studies suggested that the primary route
of metabolism of empagliflozin in humans is glucuronidation by the
uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8,
and UGT1A9.</p>
<p><a name="p975013221360088075"></a><span class="Italics">Elimination</span><br>The apparent terminal elimination
half-life of empagliflozin was estimated to be 12.4 h and apparent
oral clearance was 10.6 L/h based on the population pharmacokinetic
analysis.  Following once-daily dosing, up to 22% accumulation, with
respect to plasma AUC, was observed at steady-state, which was consistent
with empagliflozin half-life.  Following administration of an oral
[<span class="Sup">14</span>C]-empagliflozin solution to healthy
subjects, approximately 95.6% of the drug-related radioactivity was
eliminated in feces (41.2%) or urine (54.4%).  The majority of drug-related
radioactivity recovered in feces was unchanged parent drug and approximately
half of drug-related radioactivity excreted in urine was unchanged
parent drug.</p>
<p><a name="p99844221360088361"></a><span class="Italics">Specific Populations</span><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br>In patients with mild (eGFR: 60 to less than 90 mL/min/1.73
m<span class="Sup">2</span>), moderate (eGFR: 30 to less than 60
mL/min/1.73 m<span class="Sup">2</span>), and severe (eGFR: less
than 30 mL/min/1.73 m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
and subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>/end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) patients,
AUC of empagliflozin increased by approximately 18%, 20%, 66%, and
48%, respectively, compared to subjects with normal renal function.
 Peak plasma levels of empagliflozin were similar in subjects with
moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>/ESRD compared to patients
with normal renal function.  Peak plasma levels of empagliflozin were
roughly 20% higher in subjects with mild and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
as compared to subjects with normal renal function.  Population pharmacokinetic
analysis showed that the apparent oral clearance of empagliflozin
decreased, with a decrease in eGFR leading to an increase in drug
exposure.  However, the fraction of empagliflozin that was excreted
unchanged in urine, and urinary glucose excretion, declined with decrease
in eGFR.</p>
<p><a name="p100135221360088391"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br>In subjects with mild,
moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> according to the Child-Pugh
classification, AUC of empagliflozin increased by approximately 23%,
47%, and 75%, and C<span class="Sub">max</span> increased by approximately
4%, 23%, and 48%, respectively, compared to subjects with normal hepatic
function.</p>
<p><a name="p100245221360088415"></a><span class="Underline">Effects of Age, Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index, Gender, and Race</span><br>Based on the population PK analysis, age, body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI),
gender and race (Asians versus primarily Whites) do not have a clinically
meaningful effect on pharmacokinetics of empagliflozin <span class="Italics">[see
Use in Specific Populations (<a href="#Section_8.5">8.5</a>)]</span>.</p>
<p><a name="p102582221360088490"></a><span class="Underline">Pediatric</span><br>Studies characterizing the pharmacokinetics of empagliflozin
in pediatric patients have not been performed.</p>
<p><a name="p102724221360088531"></a><span class="Italics">Drug Interactions</span><br><span class="Underline"><span class="Italics">In vitro</span> Assessment of Drug Interactions</span><br><span class="Italics">In vitro</span> data suggest that the primary
route of metabolism of empagliflozin in humans is glucuronidation
by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3,
UGT1A8, and UGT1A9.  Empagliflozin does not inhibit, inactivate, or
induce CYP450 isoforms.  Empagliflozin also does not inhibit UGT1A1.
 Therefore, no effect of empagliflozin is anticipated on concomitantly
administered drugs that are substrates of the major CYP450 isoforms
or UGT1A1.  The effect of UGT induction (e.g., induction by rifampicin
or any other UGT enzyme inducer) on empagliflozin exposure has not
been evaluated.</p>
<p><a name="p102733221360088542"></a>Empagliflozin
is a substrate for P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP), but it does not inhibit these efflux transporters
at therapeutic doses. Based on <span class="Italics">in vitro</span> studies,
empagliflozin is considered unlikely to cause interactions with drugs
that are P-gp substrates.  Empagliflozin is a substrate of the human
uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2.
 Empagliflozin does not inhibit any of these human uptake transporters
at clinically relevant plasma concentrations and, therefore, no effect
of empagliflozin is anticipated on concomitantly administered drugs
that are substrates of these uptake transporters.</p>
<p><a name="p105004221360088592"></a><span class="Underline"><span class="Italics">In vivo</span> Assessment
of Drug Interactions</span><br>No dose adjustment of
JARDIANCE is recommended when coadministered with commonly prescribed
medicinal products based on results of the described pharmacokinetic
studies.  Empagliflozin pharmacokinetics were similar with and without
coadministration of metformin, glimepiride, pioglitazone, sitagliptin,
linagliptin, warfarin, verapamil, ramipril, simvastatin, hydrochlorothiazide,
and torasemide in healthy volunteers (see Figure 1).  The observed
increases in overall exposure (AUC) of empagliflozin following coadministration
with gemfibrozil, rifampicin, or probenecid are not clinically relevant.
 In subjects with normal renal function, coadministration of empagliflozin
with probenecid resulted in a 30% decrease in the fraction of empagliflozin
excreted in urine without any effect on 24-hour urinary glucose excretion.
 The relevance of this observation to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
is unknown.</p>
<p><a name="p105372221360088791"></a><span class="Bold">Figure
1â€ƒEffect of Various Medications on the Pharmacokinetics of Empagliflozin
as Displayed as 90% Confidence Interval of Geometric Mean AUC and
C<span class="Sub">max</span> Ratios [reference lines indicate 100%
(80% - 125%)]</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=figure-1.jpg"></div>
<p><a name="p105192221360088732"></a><span class="Sup">a</span>empagliflozin,
50 mg, once daily; <span class="Sup">b</span>empagliflozin, 25 mg,
single dose; <span class="Sup">c</span>empagliflozin, 25 mg, once
daily; <span class="Sup">d</span>empagliflozin, 10 mg, single dose</p>
<p><a name="p107523221360092768"></a>Empagliflozin had no clinically
relevant effect on the pharmacokinetics of metformin, glimepiride,
pioglitazone, sitagliptin, linagliptin, warfarin, digoxin, ramipril,
simvastatin, hydrochlorothiazide, torasemide, and oral contraceptives
when coadministered in healthy volunteers (see Figure 2).</p>
<p><a name="p107593221360092921"></a><span class="Bold">Figure 2â€ƒEffect of Empagliflozin
on the Pharmacokinetics of Various Medications as Displayed as 90%
Confidence Interval of Geometric Mean AUC and C<span class="Sub">max</span> Ratios [reference lines indicate 100% (80% - 125%)]</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=figure-2.jpg"></div>
<p><a name="p107573221360092920"></a><span class="Sup">a</span>empagliflozin,
50 mg, once daily; <span class="Sup">b</span>empagliflozin, 25 mg,
once daily; <span class="Sup">c</span>empagliflozin, 25 mg, single
dose; <span class="Sup">d</span>administered as simvastatin; <span class="Sup">e</span>administered as warfarin racemic mixture; <span class="Sup">f</span>administered as Microgynon<span class="Sup">Â®</span>; <span class="Sup">g</span>administered as ramipril</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="P30"></a><span class="Underline">Carcinogenesis</span><br>Carcinogenesis was evaluated in 2-year studies conducted in CD-1
mice and Wistar rats.  Empagliflozin did not increase the incidence
of tumors in female rats dosed at 100, 300, or 700 mg/kg/day (up to
72 times the exposure from the maximum clinical dose of 25 mg).  In
male rats, <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> of the mesenteric lymph node were increased
significantly at 700 mg/kg/day or approximately 42 times the exposure
from a 25 mg clinical dose.  Empagliflozin did not increase the incidence
of tumors in female mice dosed at 100, 300, or 1000 mg/kg/day (up
to 62 times the exposure from a 25 mg clinical dose).  Renal tubule
<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas were observed in male mice at 1000 mg/kg/day,
which is approximately 45 times the exposure of the maximum clinical
dose of 25 mg.</p>
<p><a name="p82154281403556347"></a><span class="Underline">Mutagenesis</span><br>Empagliflozin was not mutagenic
or clastogenic with or without metabolic activation in the <span class="Italics">in vitro</span> Ames bacterial mutagenicity assay, the <span class="Italics">in vitro</span> L5178Y tk<span class="Sup">+/-</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>
cell assay, and an <span class="Italics">in vivo</span> micronucleus assay in
rats.</p>
<p><a name="p36097221360092998"></a><span class="Underline">Impairment
of Fertility</span><br>Empagliflozin had no effects on
mating, fertility or early embryonic development in treated male or
female rats up to the high dose of 700 mg/kg/day (approximately 155
times the 25 mg clinical dose in males and females, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14â€ƒâ€ƒCLINICAL STUDIES</h1>
<p class="First"><a name="P32"></a>JARDIANCE has been studied as monotherapy and in combination
with metformin, sulfonylurea, pioglitazone, linagliptin, and insulin.
 JARDIANCE has also been studied in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><a name="p33533221360093037"></a>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, treatment
with JARDIANCE reduced hemoglobin A1c (HbA1c), compared to placebo.
 The reduction in HbA1c for JARDIANCE compared with placebo was observed
across subgroups including gender, race, geographic region, baseline
BMI and duration of disease.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Monotherapy</h2>
<p class="First"><a name="p38412221360093106"></a>A total of 986 patients with type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a double-blind, placebo-controlled study
to evaluate the efficacy and safety of JARDIANCE monotherapy.</p>
<p><a name="p110174221360093109"></a>Treatment-naÃ¯ve patients with
inadequately controlled type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> entered an open-label placebo
run-in for 2 weeks.  At the end of the run-in period, patients who
remained inadequately controlled and had an HbA1c between 7 and 10%
were randomized to placebo, JARDIANCE 10 mg, JARDIANCE 25 mg, or a
reference comparator.</p>
<p><a name="p87196281407244974"></a>At Week 24, treatment with JARDIANCE 10 mg or 25 mg daily provided
statistically significant reductions in HbA1c (p-value &lt;0.0001),
fasting plasma glucose (FPG), and body weight compared with placebo
(see Table 4 and Figure 3).</p>
<a name="t11018722"></a><table border="0" width="100%">
<caption><span>Table 4â€ƒResults at Week 24 From a Placebo-Controlled Monotherapy
Study of JARDIANCE</span></caption>
<colgroup>
<col valign="top" width="2.5%">
<col width="37.5%">
<col valign="top" width="20%">
<col valign="top" width="20%">
<col valign="top" width="20%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 24.  At Week 24, 9.4%, 9.4%, and 30.7% was imputed for
patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively.<br><span class="Sup">b</span>ANCOVA derived
p-value &lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
renal function, and region.  Body weight and FPG: same model used
as for HbA1c but additionally including baseline body weight/baseline
FPG, respectively.)<br><span class="Sup">c</span>FPG (mg/dL);
for JARDIANCE 10 mg, n=223, for JARDIANCE 25 mg, n=223, and for placebo,
n=226</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>10 mg<br>N=224</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>25 mg<br>N=224</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo<br>N=228</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">0.1</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (97.5% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.7<span class="Sup">b</span> (-0.9, -0.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.9<span class="Sup">b</span>  (-1.0, -0.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Patients [n (%)] achieving HbA1c
&lt;7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">72 (35%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">88 (44%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">25 (12%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5">
<span class="Bold">FPG (mg/dL)</span><span class="Sup">c</span>
</td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">153</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">153</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">155</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-19</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-25</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-31 (-37, -26)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-36 (-42, -31)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean) in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">78</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">78</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">78</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-3.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.5<span class="Sup">b</span> (-3.1, -1.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.8<span class="Sup">b</span> (-3.4, -2.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
</tbody>
</table>
<p><a name="p1204510221360094028"></a><span class="Bold">Figure 3â€ƒAdjusted
Mean HbA1c Change at Each Time Point (Completers) and at Week 24 (mITT
Population) - LOCF</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=figure-3.jpg"></div>
<p><a name="p120435221360094344"></a>At Week 24, the systolic blood pressure was
statistically significantly reduced compared to placebo by -2.6 mmHg
(placebo-adjusted, p-value=0.0231) in patients randomized to 10 mg
of JARDIANCE and by -3.4 mmHg (placebo-corrected, p-value=0.0028)
in patients randomized to 25 mg of JARDIANCE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s122925221360097856"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination Therapy</h2>
<p class="First"><a name="p358815221360094434"></a><span class="Italics">Add-On Combination Therapy with Metformin</span><br>A total of 637 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated
in a double-blind, placebo-controlled study to evaluate the efficacy
and safety of JARDIANCE in combination with metformin.</p>
<p><a name="p122984221360094436"></a>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
inadequately controlled on at least 1500 mg of metformin per day entered
an open-label 2 week placebo run-in.  At the end of the run-in period,
patients who remained inadequately controlled and had an HbA1c between
7 and 10% were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE
25 mg.</p>
<p><a name="p100323281407245698"></a>At Week 24,
treatment with JARDIANCE 10 mg or 25 mg daily provided statistically
significant reductions in HbA1c (p-value &lt;0.0001), FPG, and body
weight compared with placebo (see Table 5).</p>
<a name="t12297822"></a><table border="0" rules="none" width="100%">
<caption><span>Table 5â€ƒResults at Week 24 From a Placebo-Controlled Study
for JARDIANCE used in Combination with Metformin</span></caption>
<colgroup>
<col valign="top" width="2%">
<col width="56%">
<col valign="top" width="14%">
<col valign="top" width="14%">
<col valign="top" width="14%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 24.  At Week 24, 9.7%, 14.1%, and 24.6% was imputed for
patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively.<br><span class="Sup">b</span>ANCOVA p-value
&lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
renal function, and region.  Body weight and FPG: same model used
as for HbA1c but additionally including baseline body weight/baseline
FPG, respectively.)<br><span class="Sup">c</span>FPG (mg/dL);
for JARDIANCE 10 mg, n=216, for JARDIANCE 25 mg, n=213, and for placebo,
n=207</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>10 mg + Metformin<br>N=217</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>25 mg + Metformin<br>N=213</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo + Metformin<br>N=207</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7.9</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.1</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo + metformin
(adjusted mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.6<span class="Sup">b</span> (-0.7, -0.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.6<span class="Sup">b</span> (-0.8, -0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Patients [n (%)] achieving HbA1c
&lt;7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">75 (38%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">74 (39%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">23 (13%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5">
<span class="Bold">FPG (mg/dL)</span><span class="Sup">c</span>
</td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">155</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">149</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">156</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-22</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo + metformin
(adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline mean in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">82</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">82</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">80</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.5</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.0<span class="Sup">b</span> (-2.6, -1.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.5<span class="Sup">b</span> (-3.1, -1.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
</tbody>
</table>
<p><a name="p1361611221360095051"></a>At Week 24, the systolic
blood pressure was statistically significantly reduced compared to
placebo by -4.1 mmHg (placebo-corrected, p-value &lt;0.0001) for JARDIANCE
10 mg and -4.8 mmHg (placebo-corrected, p-value &lt;0.0001) for JARDIANCE
25 mg.</p>
<p><a name="p138675221360095094"></a><span class="Italics">Add-On
Combination Therapy with Metformin and Sulfonylurea</span><br>A total of 666 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a double-blind,
placebo-controlled study to evaluate the efficacy and safety of JARDIANCE
in combination with metformin plus a sulfonylurea.</p>
<p><a name="p115649281407246197"></a>Patients with inadequately controlled type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> on at least 1500 mg per day of metformin and on a sulfonylurea,
entered a 2 week open-label placebo run-in.  At the end of the run-in,
patients who remained inadequately controlled and had an HbA1c between
7% and 10% were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE
25 mg.</p>
<p><a name="p138577221360095125"></a>Treatment with
JARDIANCE 10 mg or 25 mg daily provided statistically significant
reductions in HbA1c (p-value &lt;0.0001), FPG, and body weight compared
with placebo (see Table 6).</p>
<a name="t13873522"></a><table border="0" width="100%">
<caption><span>Table 6â€ƒResults at Week 24 from a Placebo-Controlled Study
for JARDIANCE in Combination with Metformin and Sulfonylurea</span></caption>
<colgroup>
<col valign="top" width="2.5%">
<col width="37.5%">
<col valign="top" width="20%">
<col valign="top" width="20%">
<col valign="top" width="20%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 24.  At Week 24, 17.8%, 16.7%, and 25.3% was imputed
for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively.<br><span class="Sup">b</span>ANCOVA p-value
&lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
renal function, and region.  Body weight and FPG: same model used
as for HbA1c but additionally including baseline body weight/baseline
FPG, respectively.)<br><span class="Sup">c</span>FPG (mg/dL);
for JARDIANCE 10 mg, n=225, for JARDIANCE 25 mg, n=215, for placebo,
n=224</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE<br>10 mg + Metformin<br>+ SU<br>N=225</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE<br> 25 mg + Metformin<br>+ SU<br>N=216</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo
+ Metformin + SU<br>N=225</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8.2</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.2</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.6<span class="Sup">b</span> (-0.8, -0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.6<span class="Sup">b</span> (-0.7, -0.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Patients [n (%)] achieving HbA1c
&lt;7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">55 (26%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">65 (32%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">20 (9%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">FPG  (mg/dL)<span class="Sup">c</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">151</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">156</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">152</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-23</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-23</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline mean in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">77</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">78</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">76</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-3.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-0.5</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.4<span class="Sup">b</span> (-3.0, -1.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">-2.7<span class="Sup">b</span> (-3.3, -2.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
</tbody>
</table>
<p><a name="p335781301435856917"></a><span class="Italics">In Combination
with Linagliptin as Add-On to Metformin Therapy</span><br>A total of 686 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a double-blind,
active-controlled study to evaluate the efficacy and safety of JARDIANCE
10 mg or 25 mg in combination with linagliptin 5 mg compared to the
individual components.</p>
<p><a name="p335831301435856935"></a>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on at least
1500 mg of metformin per day entered a single-blind placebo run-in
period for 2 weeks.  At the end of the run-in period, patients who
remained inadequately controlled and had an HbA1c between 7 and 10.5%
were randomized 1:1:1:1:1 to one of 5 active-treatment arms of JARDIANCE
10 mg or 25 mg, linagliptin 5 mg, or linagliptin 5 mg in combination
with 10 mg or 25 mg JARDIANCE as a fixed dose combination tablet.</p>
<p><a name="p335811301435856933"></a>At Week 24, JARDIANCE 10 mg or
25 mg used in combination with linagliptin 5 mg provided statistically
significant improvement in HbA1c (p-value &lt;0.0001) and FPG (p-value
&lt;0.001) compared to the individual components in patients who had
been inadequately controlled on metformin.  Treatment with JARDIANCE/linagliptin
25 mg/5 mg or JARDIANCE/linagliptin 10 mg/5 mg daily also resulted
in a statistically significant reduction in body weight compared to
linagliptin 5 mg (p-value &lt;0.0001).  There was no statistically
significant difference in body weight compared to JARDIANCE alone.</p>
<p><a name="p148956221360095705"></a><span class="Italics">Active-Controlled Study
versus Glimepiride in Combination with Metformin </span><br>The efficacy of JARDIANCE was evaluated in a double-blind, glimepiride-controlled,
study in 1545 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with insufficient glycemic
control despite metformin therapy.</p>
<p><a name="p148567221360095728"></a>Patients with inadequate glycemic control
and an HbA1c between 7% and 10% after a 2-week run-in period were
randomized to glimepiride or JARDIANCE 25 mg.</p>
<p><a name="p133385281407246577"></a>At Week 52, JARDIANCE 25 mg and glimepiride
lowered HbA1c and FPG (see Table 7, Figure 4).  The difference in
observed effect size between JARDIANCE 25 mg and glimepiride excluded
the pre-specified non-inferiority margin of 0.3%.  The mean daily
dose of glimepiride was 2.7 mg and the maximal approved dose in the
United States is 8 mg per day.</p>
<a name="t14892722"></a><table border="0" width="100%">
<caption><span> Table 7	Results at Week 52 from an Active-Controlled Study
Comparing JARDIANCE to Glimepiride as Add-On Therapy in Patients Inadequately
Controlled on Metformin</span></caption>
<colgroup>
<col width="2%">
<col width="54%">
<col width="22%">
<col width="22%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute data
missing at Week 52.  At Week 52, data was imputed for 15.3% and 21.9%
of patients randomized to JARDIANCE 25 mg and glimepiride, respectively.<br><span class="Sup">b</span>Non-inferior, ANCOVA model p-value &lt;0.0001
(HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function,
and region)<br><span class="Sup">c</span>ANCOVA p-value
&lt;0.0001 (Body weight and FPG: same model used as for HbA1c but
additionally including baseline body weight/baseline FPG, respectively.)<br><span class="Sup">d</span>FPG (mg/dL); for JARDIANCE 25 mg, n=764,
for placebo, n=779</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg + Metformin<br>N=765</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Glimepiride
+ Metformin<br>N=780</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="4"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.9</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from glimepiride (adjusted
mean) (97.5% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.07<span class="Sup">b</span> (-0.15, 0.01)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="4"><span class="Bold">FPG (mg/dL)<span class="Sup">d</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">150</td>
<td class="Botrule Lrule Rrule Toprule" align="center">150</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-19</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-9</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from glimepiride (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="4"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline mean in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">82.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">83</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-3.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from glimepiride (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-5.9<span class="Sup">c</span> (-6.3, -5.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
</tbody>
</table>
<p><a name="p164074221360096360"></a><span class="Bold">Figure 4â€ƒAdjusted
mean HbA1c Change at Each Time Point (Completers) and at Week 52 (mITT
Population) - LOCF</span></p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=figure-4.jpg"></div>
<p><a name="p163907221360096383"></a>At Week 52, the adjusted mean change from
baseline in systolic blood pressure was -3.6 mmHg, compared to 2.2
mmHg for glimepiride.  The differences between treatment groups for
systolic blood pressure was statistically significant (p-value &lt;0.0001).</p>
<p><a name="p338093301435857297"></a>At Week 104, the adjusted mean
change from baseline in HbA1c was -0.75% for JARDIANCE 25 mg and -0.66%
for glimepiride.  The adjusted mean treatment difference was -0.09%
with a 97.5% confidence interval of (-0.32%, 0.15%), excluding the
pre-specified non-inferiority margin of 0.3%.  The mean daily dose
of glimepiride was 2.7 mg and the maximal approved dose in the United
States is 8 mg per day.   The Week 104 analysis included data with
and without concomitant glycemic rescue medication, as well as off-treatment
data.  Missing data for patients not providing any information at
the visit were imputed based on the observed off-treatment data. 
In this multiple imputation analysis, 13.9% of the data were imputed
for JARDIANCE 25 mg and 12.9% for glimepiride.</p>
<p><a name="p338112301435857304"></a>At Week 104, JARDIANCE 25 mg daily resulted
in a statistically significant difference in change from baseline
for body weight compared to glimepiride (-3.1 kg for JARDIANCE 25
mg vs. +1.3 kg for glimepiride; ANCOVA-LOCF, p-value &lt;0.0001).</p>
<p><a name="p1643014221360096426"></a><span class="Italics">Add-On Combination Therapy
with Pioglitazone with or without Metformin</span><br>A
total of 498 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a double-blind,
placebo-controlled study to evaluate the efficacy and safety of JARDIANCE
in combination with pioglitazone, with or without metformin.</p>
<p><a name="p164217221360096428"></a>Patients with inadequately controlled
type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> on metformin at a dose of at least 1500 mg per day
and pioglitazone at a dose of at least 30 mg per day were placed into
an open-label placebo run-in for 2 weeks.  Patients with inadequate
glycemic control and an HbA1c between 7% and 10% after the run-in
period were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE 25
mg.</p>
<p><a name="p164127221360096429"></a>Treatment with
JARDIANCE 10 mg or 25 mg daily resulted in statistically significant
reductions in HbA1c (p-value &lt;0.0001), FPG, and body weight compared
with placebo (see Table 8).</p>
<a name="t16683722"></a><table border="0" width="100%">
<caption><span>Table 8â€ƒResults of Placebo-Controlled Study for JARDIANCE
in Combination Therapy with Pioglitazone</span></caption>
<colgroup>
<col width="2.5%">
<col width="37.5%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 24.  At Week 24, 10.9%, 8.3%, and 20.6% was imputed for
patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively.<br><span class="Sup">b</span>ANCOVA p-value
&lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
renal function, and background medication.  Body weight and FPG: same
model used as for HbA1c but additionally including baseline body weight/baseline
FPG, respectively.)<br><span class="Sup">c</span>FPG (mg/dL);
for JARDIANCE 10 mg, n=163</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE 10 mg +<br>Pioglitazone<br>N=165</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE 25 mg +<br>Pioglitazone<br>N=168</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo + Pioglitazone<br>N=165</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.2</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.1</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo + pioglitazone
(adjusted mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.5<span class="Sup">b</span> (-0.7, -0.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6<span class="Sup">b</span> (-0.8, -0.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Patients [n (%)] achieving HbA1c
&lt;7% </td>
<td class="Botrule Lrule Rrule Toprule" align="center">36 (24%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">48 (30%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12 (8%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5">
<span class="Bold">FPG (mg/dL)</span><span class="Sup">c</span>
</td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">152</td>
<td class="Botrule Lrule Rrule Toprule" align="center">152</td>
<td class="Botrule Lrule Rrule Toprule" align="center">152</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-17</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-22</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo + pioglitazone
(adjusted mean) (97.5% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-23<span class="Sup">b</span> (-31.8, -15.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-28<span class="Sup">b</span> (-36.7, -20.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline mean in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">78</td>
<td class="Botrule Lrule Rrule Toprule" align="center">79</td>
<td class="Botrule Lrule Rrule Toprule" align="center">78</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-2.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-2.6<span class="Sup">b</span> (-3.4, -1.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-2.4<span class="Sup">b</span> (-3.2, -1.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
</tbody>
</table>
<p><a name="p176654221360096967"></a><span class="Italics">Add-On Combination
with Insulin with or without Metformin and/or Sulfonylureas</span><br>A total of 494 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately
controlled on insulin, or insulin in combination with oral drugs participated
in a double-blind, placebo-controlled study to evaluate the efficacy
of JARDIANCE as add-on therapy to insulin over 78 weeks.</p>
<p><a name="p177084221360096969"></a>Patients entered a 2-week placebo
run-in period on basal insulin (e.g., insulin glargine, insulin detemir,
or NPH insulin) with or without metformin and/or sulfonylurea background
therapy.  Following the run-in period, patients with inadequate glycemic
control were randomized to the addition of JARDIANCE 10 mg, JARDIANCE
25 mg, or placebo.  Patients were maintained on a stable dose of insulin
prior to enrollment, during the run-in period, and during the first
18 weeks of treatment.  For the remaining 60 weeks, insulin could
be adjusted.  The mean total daily insulin dose at baseline for JARDIANCE
10 mg, 25 mg, and placebo was 45 IU, 48 IU, and 48 IU, respectively.</p>
<p><a name="p159114281407247561"></a>JARDIANCE used in combination
with insulin (with or without metformin and/or sulfonylurea) provided
statistically significant reductions in HbA1c and FPG compared to
placebo after both 18 and 78 weeks of treatment (see Table 9).  JARDIANCE
10 mg or 25 mg daily also resulted in statistically significantly
greater percent body weight reduction compared to placebo.</p>
<a name="t3344222"></a><table border="0" width="100%">
<caption><span>Table 9â€ƒResults at Week 18 and 78 for a Placebo-Controlled
Study for JARDIANCE in Combination with Insulin</span></caption>
<colgroup>
<col width="2.5%">
<col width="19.5%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="8">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 18 and 78.  At Week 18, 21.3%, 30.3%, and 21.8% was imputed
for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively.  At Week 78, 32.5%, 38.1% and 42.4% was imputed for
patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively<br><span class="Sup">b</span>ANCOVA p-value
&lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
and region; FPG: MMRM model includes baseline FPG, baseline HbA1c,
treatment, region, visit and visit by treatment interaction.  Body
weight: MMRM model includes baseline body weight, baseline HbA1c,
treatment, region, visit and visit by treatment interaction.<br><span class="Sup">c</span>p-value=0.0049<br><span class="Sup">d</span>p-value=0.0052<br><span class="Sup">e</span>p-value=0.0463</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">18 weeks<br>(no insulin adjustment)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">78 weeks<br>(adjustable insulin dose after
18 weeks)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>10 mg +<br>Insulin<br>N=169</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>25 mg +<br>Insulin<br>N=155</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo + <br>Insulin<br>N=170</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>10 mg +<br>Insulin<br>N=169</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE<br>25 mg +<br>Insulin<br>N=155</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo + <br>Insulin<br>N=170</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.2</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.1</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (97.5% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6<span class="Sup">b</span> (-0.8, -0.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7<span class="Sup">b</span> (-0.9, -0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.5<span class="Sup">b</span> (-0.7, -0.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.7<span class="Sup">b</span> (-0.9, -0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Patients (%) achieving HbA1c &lt;7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">17.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.7</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8"><span class="Bold">FPG (mg/dL) </span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">138</td>
<td class="Botrule Lrule Rrule Toprule" align="center">146</td>
<td class="Botrule Lrule Rrule Toprule" align="center">142</td>
<td class="Botrule Lrule Rrule Toprule" align="center">138</td>
<td class="Botrule Lrule Rrule Toprule" align="center">146</td>
<td class="Botrule Lrule Rrule Toprule" align="center">142</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean,
SE)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-17.9 (3.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-19.1 (3.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10.4 (3.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-10.1 (3.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-15.2 (3.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.8 (3.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-28.2<span class="Sup">b</span> (-37.0, -19.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-29.5<span class="Sup">b</span> (-38.4, -20.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-12.9<span class="Sup">c</span> (-21.9, 3.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-17.9<span class="Sup">b</span> (-27.0, -8.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8"><span class="Bold">Body Weight</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline mean in kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">92</td>
<td class="Botrule Lrule Rrule Toprule" align="center">95</td>
<td class="Botrule Lrule Rrule Toprule" align="center">90</td>
<td class="Botrule Lrule Rrule Toprule" align="center">92</td>
<td class="Botrule Lrule Rrule Toprule" align="center">95</td>
<td class="Botrule Lrule Rrule Toprule" align="center">90</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">% change from baseline (adjusted
mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-2.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-2.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.7</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.7<span class="Sup">d</span> (-3.0, -0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.3<span class="Sup">e</span> (-2.5, -0.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-3.0<span class="Sup">b</span> (-4.4, -1.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-3.0<span class="Sup">b</span> (-4.4, -1.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
</tbody>
</table>
<p><a name="p338202301435857800"></a><span class="Italics">Add-on Combination
with MDI Insulin with or without Metformin</span><br>A total
of 563 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on multiple
daily injections (MDI) of insulin (total daily dose &gt;60 IU), alone
or in combination with metformin, participated in a double-blind,
placebo-controlled study to evaluate the efficacy of JARDIANCE as
add-on therapy to MDI insulin over 18 weeks.</p>
<p><a name="p338182301435857798"></a>Patients entered a 2-week placebo run-in
period on MDI insulin with or without metformin background therapy.
 Following the run-in period, patients with inadequate glycemic control
were randomized to the addition of JARDIANCE 10 mg, JARDIANCE 25 mg,
or placebo.  Patients were maintained on a stable dose of insulin
prior to enrollment, during the run-in period, and during the first
18 weeks of treatment.  The mean total daily insulin dose at baseline
for JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo was 88.6 IU, 90.4
IU, and 89.9 IU, respectively.</p>
<p><a name="p338145301435857793"></a>JARDIANCE 10 mg or 25 mg daily used in combination
with MDI insulin (with or without metformin) provided statistically
significant reductions in HbA1c compared to placebo after 18 weeks
of treatment (see Table 10).</p>
<a name="t29459630"></a><table border="0" width="100%">
<caption><span>Table 10â€ƒResults at Week 18 for a Placebo-Controlled Study
for JARDIANCE in Combination with Insulin and with or without Metformin</span></caption>
<colgroup>
<col width="2.5%">
<col width="19.5%">
<col width="13%">
<col width="13%">
<col width="13%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span>Modified intent to treat
population.  Last observation on study (LOCF) was used to impute missing
data at Week 18.  At Week 18, 23.7%, 22.8% and 23.4% was imputed for
patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo,
respectively. <br><span class="Sup">b</span>ANCOVA p-value
&lt;0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment,
renal function, geographical region, and background medication).</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE 10 mg<br>+ Insulin<br>+/- Metformin<br>N=186</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">JARDIANCE 25 mg<br>+ Insulin<br>+/- Metformin<br>N=189</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo <br>+ Insulin<br>+/- Metformin<br>N=188</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">HbA1c (%)<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Baseline (mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.3</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Change from baseline (adjusted mean)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.5</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule">Difference from placebo (adjusted
mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.4<span class="Sup">b</span> (-0.6, -0.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.5<span class="Sup">b</span> (-0.7, -0.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
</tbody>
</table>
<p><a name="p338222301435857810"></a>During an extension period
with treatment for up to 52 weeks, insulin could be adjusted to achieve
defined glucose target levels.  The change from baseline in HbA1c
was maintained from 18 to 52 weeks with both JARDIANCE 10 mg and 25
mg.  After 52 weeks, JARDIANCE 10 mg or 25 mg daily resulted in statistically
greater percent body weight reduction compared to placebo (p-value
&lt;0.0001).  The mean change in body weight from baseline was -1.95
kg for JARDIANCE 10 mg, and -2.04 kg for JARDIANCE 25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p15373221360097892"></a>A total of 738 patients with type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a baseline eGFR less than 90 mL/min/1.73 m<span class="Sup">2</span> participated in a randomized, double-blind, placebo-controlled,
parallel-group to evaluate the efficacy and safety of JARDIANCE in
patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  The trial population
comprised of 290 patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 60 to less
than 90 mL/min/1.73 m<span class="Sup">2</span>), 374 patients with
moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span>), and 74 with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR less
than 30 mL/min/1.73 m<span class="Sup">2</span>).  A total of 194
patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had a baseline eGFR of 30
to less than 45 mL/min/1.73 m<span class="Sup">2 </span>and 180
patients a baseline eGFR of 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p><a name="p202635221360097894"></a>At
Week 24, JARDIANCE 25 mg provided statistically significant reduction
in HbA1c relative to placebo in patients with mild to moderate renal
impairment (see Table 11).  A statistically significant reduction
relative to placebo was also observed with JARDIANCE 25 mg in patients
with either mild [-0.7 (95% CI: -0.9, -0.5)] or moderate [-0.4 (95%
CI: -0.6, -0.3)] <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and with JARDIANCE 10 mg in patients
with mild [-0.5 (95% CI: -0.7, -0.3)] <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><a name="p166517281407248377"></a>The glucose lowering efficacy
of JARDIANCE 25 mg decreased with decreasing level of renal function
in the mild to moderate range.  Least square mean Hb1Ac changes at
24 weeks were -0.6%, -0.5%, and -0.2% for those with a baseline eGFR
of 60 to less than 90 mL/min/1.73 m<span class="Sup">2</span>, 45
to less than 60 mL/min/1.73 m<span class="Sup">2</span>, and 30
to less than 45 mL/min/1.73 m<span class="Sup">2</span>, respectively <span class="Italics">[see Dosage and Administration (<a href="#Section_2">2</a>)
and Use in Specific Populations (<a href="#Section_8.6">8.6</a>)]</span>.  For placebo, least square mean HbA1c changes at 24
weeks were 0.1%, -0.1%, and 0.2% for patients with a baseline eGFR
of 60 to less than 90 mL/min/1.73 m<span class="Sup">2</span>, 45
to less than 60 mL/min/1.73 m<span class="Sup">2</span>, and 30
to less than 45 mL/min/1.73 m<span class="Sup">2</span>, respectively.</p>
<a name="t20256922"></a><table border="0" width="100%">
<caption><span>Table 11â€ƒResults at Week 24 (LOCF) of Placebo-Controlled
Study for JARDIANCE in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<colgroup>
<col width="2%">
<col width="48%">
<col width="50%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span>p-value &lt;0.0001
(HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function,
and background medication)<br><span class="Sup">b</span>eGFR 30 to less than 90 mL/min/1.73 m<span class="Sup">2</span>- Modified intent to treat population. Last observation on study
(LOCF) was used to impute missing data at Week 24.  At Week 24, 24.6%
and 26.2% was imputed for patients randomized to JARDIANCE 25 mg and
placebo, respectively.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Mild and
Moderate Impairment<span class="Sup">b</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">JARDIANCE
25 mg</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">HbA1c</span></td></tr>
<tr>
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule" valign="top">Number of patients</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n=284</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule">Â </td>
<td class="Botrule Rrule Toprule" valign="top">Comparison vs placebo
(adjusted mean) (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.5<span class="Sup">a</span> (-0.6, -0.4)</td>
</tr>
</tbody>
</table>
<p><a name="p117782221360098782"></a>For patients with severe
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the analyses of changes in HbA1c and FPG showed
no discernible treatment effect of JARDIANCE 25 mg compared to placebo <span class="Italics">[see Dosage and Administration (<a href="#Section_2.2">2.2</a>) and Use in Specific Populations (<a href="#Section_8.6">8.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16â€ƒâ€ƒHOW
SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="P34"></a>JARDIANCE tablets are available in 10 mg and 25 mg strengths as follows:</p>
<p><a name="p177105281403622858"></a><span class="Bold">10 mg tablets:</span> 
<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, round, biconvex and bevel-edged, film-coated tablets
debossed with â€œS 10â€? on one side and the Boehringer Ingelheim company
symbol on the other side.<br>Bottles of 30 (NDC 0597-0152-30)<br>Bottles of 90 (NDC 0597-0152-90)<br>Cartons containing 3
<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 10 tablets each (3 x 10) (NDC 0597-0152-37), institutional
pack.</p>
<p><a name="p204901221360098841"></a><span class="Bold">25 mg tablets:</span> <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, oval, biconvex film-coated tablets, debossed with â€œS
25â€? on one side and the Boehringer Ingelheim company symbol on the
other side.<br>Bottles of 30 (NDC 0597-0153-30)<br>Bottles of 90 (NDC 0597-0153-90)<br>Cartons containing 3
<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 10 tablets each (3 x 10) (NDC 0597-0153-37), institutional
pack.</p>
<p><a name="p133293221360098888"></a>Dispense in a
well-closed container as defined in the USP.</p>
<p><a name="p133190221360098890"></a><span class="Italics">Storage</span><br><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F)</span> [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="p194854281407248763"></a>Advise the patient to read the
FDA-approved patient labeling (Patient Information).</p>
<p><a name="p307612221360098970"></a><span class="Underline">Instructions</span><br>Instruct patients to read the Patient Information before starting
JARDIANCE therapy and to reread it each time the prescription is renewed.
Instruct patients to inform their doctor or pharmacist if they develop
any unusual symptom, or if any known symptom persists or worsens.</p>
<p><a name="p187235221360098972"></a>Inform patients of the potential
risks and benefits of JARDIANCE and of alternative modes of therapy.
Also inform patients about the importance of adherence to dietary
instructions, regular physical activity, periodic blood glucose monitoring
and HbA1c testing, recognition and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and
<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and assessment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> complications.  Advise
patients to seek medical advice promptly during periods of stress
such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, as medication requirements
may change.</p>
<p><a name="p187255221360098973"></a>Instruct
patients to take JARDIANCE only as prescribed. If a dose is missed,
it should be taken as soon as the patient remembers.  Advise patients
not to double their next dose.</p>
<p><a name="p1511910221360098975"></a>Inform patients that the most common adverse
reactions associated with the use of JARDIANCE are <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>
and mycotic <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infections</span>.</p>
<p><a name="p297157281403623092"></a>Inform female patients of child bearing age
that the use of JARDIANCE during pregnancy has not been studied in
humans, and that JARDIANCE should only be used during pregnancy only
if the potential benefit justifies the potential risk to the fetus.
Based on animal data, JARDIANCE may cause fetal harm in the second
and third trimesters.  Instruct patients to report pregnancies to
their physicians as soon as possible.</p>
<p><a name="p297138281403623098"></a>Inform nursing mothers to discontinue JARDIANCE
or nursing, taking into account the importance of the drug to the
mother.  It is not known if JARDIANCE is excreted in breast milk;
however, based on animal data, JARDIANCE may cause harm to nursing
infants.</p>
<p><a name="p297193281403623111"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span><br>Inform patients that <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>
may occur with JARDIANCE and advise them to contact their healthcare
provider if they experience such symptoms <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.1">5.1</a>)]</span>.  Inform
patients that <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may increase the risk for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and
to have adequate fluid intake.</p>
<p><a name="p297362281403623146"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span><br>Inform patients of the potential for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.
Provide them with information on the symptoms of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.
Advise them to seek medical advice if such symptoms occur.</p>
<p><a name="p297434281403623161"></a><span class="Underline">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
in Females (e.g., <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span>)</span><br>Inform female
patients that vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> may occur and provide them
with information on the signs and symptoms of vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>.
Advise them of treatment options and when to seek medical advice <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.4">5.4</a>)]</span>.</p>
<p><a name="p299642281403623184"></a><span class="Underline">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Males (e.g., <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanoposthitis</span>) </span><br>Inform male patients that <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of penis (e.g.,
<span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>) may occur, especially in uncircumcised
males and patients with chronic and recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Provide
them with information on the signs and symptoms of <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> and <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>
(<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the glans or foreskin of the penis). Advise them
of treatment options and when to seek medical advice <span class="Italics">[see
Warnings and Precautions (<a href="#Section_5.4">5.4</a>)]</span>.</p>
<p><a name="p299792281403623231"></a><span class="Underline">Laboratory
Tests</span><br>Inform patients that renal function should
be assessed prior to initiation of JARDIANCE and monitored periodically
thereafter.</p>
<p><a name="p299864281403623245"></a>Inform
patients that elevated glucose in urinalysis is expected when taking
JARDIANCE.</p>
<p><a name="p299882281403623247"></a>Inform patients
that response to all diabetic therapies should be monitored by periodic
measurements of blood glucose and HbA1c levels, with a goal of decreasing
these levels toward the normal range.  Hemoglobin A1c monitoring is
especially useful for evaluating long-term glycemic control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_Info"></a><a name="section-16"></a><p></p>
<br><p class="First"><a name="p1231012221360099060"></a>Distributed by:<br>Boehringer Ingelheim
Pharmaceuticals, Inc.<br>Ridgefield, CT  06877 USA</p>
<p><a name="p207655221360099062"></a>Marketed by:<br>Boehringer
Ingelheim Pharmaceuticals, Inc.<br>Ridgefield, CT 06877 USA<br>and<br>Eli Lilly and Company<br>Indianapolis, IN
46285 USA</p>
<p><a name="p207505221360099064"></a>Licensed
from:<br>Boehringer Ingelheim International GmbH, Ingelheim,
Germany</p>
<p><a name="p200006281407249861"></a>Boehringer
Ingelheim Pharmaceuticals, Inc. either owns or uses the Jardiance<span class="Sup">Â® </span>trademark under license.</p>
<p><a name="p199703281407249864"></a>The other trademarks referenced are owned
by third parties not affiliated with Boehringer Ingelheim Pharmaceuticals,
Inc.</p>
<p><a name="p207645221360099065"></a>Copyright Â© 2015
Boehringer Ingelheim International GmbH<br>ALL RIGHTS RESERVED</p>
<p><a name="p207765221360099187"></a>IT5728GF302015<br>304584-02</p>
<p><a name="p215193281407505018"></a>IT6061D<br>304563-03</p>
<p><a name="p261295281407249923"></a>IT6062C<br>304561-02</p>
<p><a name="p261154281407249926"></a>IT6063C<br>304562-02</p>
<br>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<p class="First"><a name="p258969281407250050"></a><span class="Bold">PATIENT INFORMATION</span></p>
<p><a name="p276829281403623686"></a><span class="Bold">JARDIANCE<span class="Sup">Â®</span> (jar DEE ans)<br>(empagliflozin)<br>Tablets</span></p>
<p><a name="p202593281407250071"></a>Read this Patient
Information before you start taking JARDIANCE and each time you get
a refill. There may be new information. This information does not
take the place of talking to your doctor about your medical condition
or treatment. </p>
<p><a name="p2586110281407250080"></a><span class="Bold">What is the most important information I should know about JARDIANCE?</span><br>JARDIANCE can cause serious side effects, including:</p>
<br><ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>.</span> JARDIANCE can cause some people
to have <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (the loss of body water and salt). <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
may cause you to feel dizzy, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, light-headed, or weak, especially
when you stand up (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>).<br><br>You may be at higher risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> if you:<ul class="Disc">
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>take medicines to lower your blood pressure, including diuretics
(water pill)</li>
<li>are on low sodium (salt) diet</li>
<li>have kidney problems</li>
<li>are 65 years of age or older</li>
</ul>
</li>
<li>
<span class="Bold">Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</span> Women who take JARDIANCE
may get vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>. Symptoms of a vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>
include:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4162573" conceptname="Vaginal odor">vaginal odor</span></li>
<li>white or yellowish <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> (discharge may be lumpy
or look like cottage cheese)</li>
<li><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">vaginal itching</span></li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Yeast infection</span> of the penis (<span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>).</span>  Men who take JARDIANCE may get a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the skin around
the penis. Certain men who are not circumcised may have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of
the penis that makes it difficult to pull back the skin around the
tip of the penis. Other symptoms of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the penis include:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the penis</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the penis</li>
<li>foul smelling discharge from the penis</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the skin around penis</li>
</ul>
</li>
</ul>
<p><a name="p43678281407250747"></a>Talk to your doctor about
what to do if you get symptoms of a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the vagina
or penis. Your doctor may suggest you use an over-the-counter antifungal
medicine. Talk to your doctor right away if you use an over-the-counter
antifungal medication and your symptoms do not go away.</p>
<br><p class="ListCaption">What is JARDIANCE?</p>
<ul class="Disc">
<li>JARDIANCE is a prescription medicine used along with diet
and exercise to lower blood sugar in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>JARDIANCE is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>JARDIANCE is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased
<span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in the blood or urine).</li>
<li>It is not known if JARDIANCE is safe and effective in children
under 18 years of age.</li>
</ul>
<p><a name="p194743281403623765"></a><span class="Bold">Who should not take
JARDIANCE?</span></p>
<p class="ListCaption">Do not take JARDIANCE if you:</p>
<ul class="Disc">
<li>are allergic to empagliflozin or any of the ingredients
in JARDIANCE.  See the end of this leaflet for a list of ingredients
in JARDIANCE.</li>
<li>have severe kidney problems or are on dialysis</li>
</ul>
<p><a name="p210267221360099415"></a><span class="Bold">What should I tell
my doctor before using JARDIANCE?</span></p>
<dl class="None">
<dt></dt>
<dd>
<p class="ListCaption">Before you take JARDIANCE, tell your doctor if you:</p>
<ul class="Disc">
<li>have kidney problems</li>
<li>have liver problems</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> or problems with
urination</li>
<li>have any other medical conditions</li>
<li>are pregnant or planning to become pregnant. It is not known
if JARDIANCE will harm your unborn baby. If you are pregnant, talk
with your doctor about the best way to control your blood sugar while
you are pregnant.</li>
<li>are breastfeeding or plan to breastfeed. It is not known
if JARDIANCE passes into your breast milk.  Talk with your doctor
about the best way to feed your baby if you take JARDIANCE.</li>
</ul>
<p class="First"><a name="p3149411281407507477"></a><span class="Bold">Tell your doctor
about all the medicines you take,</span> including prescription and
over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><a name="p314956281407507486"></a>JARDIANCE may affect the way
other medicines work, and other medicines may affect how JARDIANCE
works.</p>
<p><a name="p335384281407507493"></a><span class="Bold">Especially
tell your doctor if you take:</span></p>
<ul class="Disc">
<li>diuretics (water pills)</li>
<li>insulin or other medicines that can lower your blood sugar</li>
</ul>
</dd>
</dl>
<p><a name="p194994281403722051"></a>Ask your doctor or pharmacist
for a list of these medicines if you are not sure if your medicine
is listed above.</p>
<p><a name="p2513213221360351663"></a><span class="Bold">How should I take JARDIANCE?</span></p>
<ul class="Disc">
<li>Take JARDIANCE exactly as your doctor tells you to take
it.</li>
<li>Take JARDIANCE by mouth 1 time in the morning each day,
with or without food.</li>
<li>Your doctor may change your dose if needed.</li>
<li>If you miss a dose, take it as soon as you remember.  If
you do not remember until it is time for your next dose, skip the
missed dose and go back to your regular schedule.  Do not take two
doses of JARDIANCE at the same time.  Talk with your doctor if you
have questions about a missed dose.</li>
<li>Your doctor may tell you to take JARDIANCE along with other
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. Low blood sugar can happen more often when JARDIANCE
is taken with certain other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. See â€œ<span class="Bold">What are
the possible side effects of JARDIANCE?</span>â€?</li>
<li>If you take too much JARDIANCE, call your doctor or go to
the nearest hospital emergency room right away.</li>
<li>When your body is under some types of stress, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,
<span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (such as a car <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, the amount
of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine that you need may change. Tell your doctor right
away if you have any of these conditions and follow your doctorâ€™s
instructions.</li>
<li>Check your blood sugar as your doctor tells you to.</li>
<li>Stay on your prescribed diet and exercise program while
taking JARDIANCE.</li>
<li>Talk to your doctor about how to prevent, recognize and
manage low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>), high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>),
and complications of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>Your doctor will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood
tests, including your blood sugar levels and your hemoglobin HbA1c.</li>
<li>When taking JARDIANCE, you may have sugar in your urine,
which will show up on a urine test.</li>
</ul>
<p><a name="p230798221360351867"></a><span class="Bold">What are the possible
side effects of JARDIANCE?</span></p>
<p><a name="p230667221360351879"></a><span class="Bold">JARDIANCE may cause serious side effects,
including:</span></p>
<ul class="Disc">
<li><span class="Bold">See â€œWhat is the most important information I should
know about JARDIANCE?â€?</span></li>
<li>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span>  If you take
JARDIANCE with another medicine that can cause low blood sugar, such
as a sulfonylurea or insulin, your risk of getting low blood sugar
is higher. The dose of your sulfonylurea medicine or insulin may need
to be lowered while you take JARDIANCE. Signs and symptoms of low
blood sugar may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>fast heart beat</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></li>
</ul>
<br>
</li>
<li>
<span class="Bold">kidney problems,</span> especially in people 75 years
of age or older and people who already have kidney problems</li>
<li><span class="Bold">increased fats in your blood (<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>)</span></li>
</ul>
<p><a name="p333082281407505262"></a><span class="Bold">The most common side
effects of JARDIANCE include:</span></p>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. Signs and symptoms of a urinary
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may include burning feeling when passing urine, urine
that looks cloudy, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the pelvis, or <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>.</li></ul>
<p><a name="p243561221360100430"></a>These are not all the possible
side effects of JARDIANCE.  For more information, ask your doctor
or pharmacist.</p>
<p><a name="p243581221360100432"></a>Call
your doctor for medical advice about side effects.  You may report
side effects to FDA at 1-800-FDA-1088.</p>
<p><a name="p217613281407252208"></a><span class="Bold">How should I store JARDIANCE?</span></p>
<p><a name="p135777281403722231"></a>Store JARDIANCE at
room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</p>
<p><a name="p245915221360100521"></a><span class="Bold">General information about the safe
and effective use of JARDIANCE.</span></p>
<p><a name="p245935221360100524"></a>This Patient Information summarizes the most
important information about JARDIANCE.  If you would like more information,
talk with your doctor.  You can ask your pharmacist or doctor for
information about JARDIANCE that is written for health professionals.</p>
<p><a name="p245979221360100556"></a>For more information about JARDIANCE,
go to www.jardiance.com, or scan the code below, or call Boehringer
Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.</p>
<div class="Figure"><img alt="SCAN HERE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=qr-code.jpg"></div>
<p><a name="p246063221360100570"></a><span class="Bold">What are the ingredients in JARDIANCE?</span></p>
<p><a name="p246093221360100579"></a>Active Ingredient:
 empagliflozin</p>
<p><a name="p246143221360100590"></a>Inactive
Ingredients:  lactose monohydrate, microcrystalline cellulose, hydroxypropyl
cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium
stearate.  In addition, the film coating contains the following inactive
ingredients: hypromellose, titanium dioxide, talc, polyethylene glycol,
and yellow ferric oxide.</p>
<br><br><p><a name="p248343221360100629"></a>Distributed by:<br>Boehringer Ingelheim
Pharmaceuticals, Inc.<br>Ridgefield, CT 06877 USA</p>
<p><a name="p248434221360100657"></a>Marketed by:<br>Boehringer
Ingelheim Pharmaceuticals, Inc.<br>Ridgefield, CT 06877 USA<br>and<br>Eli Lilly and Company<br>Indianapolis, IN
46285 USA</p>
<p><a name="p248486221360100717"></a>Licensed
from:<br>Boehringer Ingelheim International GmbH<br>Ingelheim, Germany</p>
<p><a name="p332803281407505310"></a>Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the
Jardiance<span class="Sup">Â®</span> trademark under license.</p>
<p><a name="p238363281407507643"></a>The other trademarks referenced
are owned by third parties not affiliated with Boehringer Ingelheim
Pharmaceuticals, Inc.</p>
<p><a name="p248634221360100745"></a>Copyright Â© 2015 Boehringer Ingelheim International GmbH</p>
<p><a name="p248643221360100754"></a>ALL RIGHTS RESERVED</p>
<br><br><p><a name="p248712221360100766"></a>IT5728GF302015<br>304584-02</p>
<p><a name="p215336281407252456"></a>IT6061D<br>304563-03</p>
<p><a name="p217884281407252454"></a>IT6062C<br>304561-02</p>
<p><a name="p215316281407252462"></a>IT6063C<br>304562-02</p>
<p><a name="p248723221360100782"></a>Revised:
June 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s254281407264518"></a><a name="section-18"></a><p></p>
<p class="First"><a name="p379281407264522"></a>JARDIANCE 10 mg - Sample Carton<br>NDC:
0597-0152-07</p>
<div class="Figure"><img alt="Jardiance 10 mg Sample Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=ct5765a.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g3776a51a-a974-317f-cc04-b1d2090e3e64"></a><a name="section-19"></a><p></p>
<p class="First"><a name="p9876678"></a>JARDIANCE 10 mg
- Carton<br>NDC: 0597-0152-37</p>
<div class="Figure"><img alt="Jardiance 10 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=ct5729a.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s183281407260747"></a><a name="section-20"></a><p></p>
<p class="First"><a name="p399281407260753"></a>JARDIANCE 10 mg - Bottle<br>NDC: 0597-0152-30</p>
<div class="Figure"><img alt="Jardiance 10 mg Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=l5731a.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s183281407505955"></a><a name="section-21"></a><p></p>
<p class="First"><a name="p4010281407505962"></a>JARDIANCE 25 mg - Sample Carton<br>NDC:
0597-0153-07</p>
<div class="Figure"><img alt="Jardiance 25 mg Sample Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=ct5766b.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g1830c6f4-44e4-2087-94a4-57cbb377a1eb"></a><a name="section-22"></a><p></p>
<p class="First"><a name="p214281403724624"></a>JARDIANCE
25 mg - Carton<br>NDC: 0597-0153-37</p>
<div class="Figure"><img alt="Jardiance 25 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=ct5742a.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s183281407261116"></a><a name="section-23"></a><p></p>
<p class="First"><a name="p399281407261122"></a>JARDIANCE 25 mg - Bottle<br>NDC: 0597-0153-30</p>
<div class="Figure"><img alt="Jardiance 25 mg Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&amp;name=l5735a.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>JARDIANCEÂ 		
					</strong><br><span class="contentTableReg">empagliflozin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0152</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>empagliflozin</strong> (empagliflozin) </td>
<td class="formItem">empagliflozin</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">S;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0152-37</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0597-0152-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0597-0152-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0597-0152-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0597-0152-70</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204629</td>
<td class="formItem">08/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>JARDIANCEÂ 		
					</strong><br><span class="contentTableReg">empagliflozin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0153</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>empagliflozin</strong> (empagliflozin) </td>
<td class="formItem">empagliflozin</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">S;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0153-37</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0597-0153-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0597-0153-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0597-0153-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0597-0153-70</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204629</td>
<td class="formItem">08/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc.
							(603175944)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc. (603175944)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH and Co. KG</td>
<td class="formItem"></td>
<td class="formItem">551147440</td>
<td class="formItem">MANUFACTURE(0597-0152, 0597-0153), LABEL(0597-0152, 0597-0153), PACK(0597-0152, 0597-0153), API MANUFACTURE(0597-0152, 0597-0153)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane, Inc.</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">LABEL(0597-0152, 0597-0153)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sixarp, Michigan</td>
<td class="formItem"></td>
<td class="formItem">016329513</td>
<td class="formItem">LABEL(0597-0152, 0597-0153)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sixarp, Ohio</td>
<td class="formItem"></td>
<td class="formItem">831738443</td>
<td class="formItem">LABEL(0597-0152, 0597-0153)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>540db802-c3c5-34b5-b717-48b9b6a87898</div>
<div>Set id: faf3dd6a-9cd0-39c2-0d2e-232cb3f67565</div>
<div>Version: 2</div>
<div>Effective Time: 20150630</div>
</div>
</div>Â <div class="DistributorName">Boehringer Ingelheim Pharmaceuticals, Inc.</div></p>
</body></html>
